1. Home
  2. CRSP vs LPL Comparison

CRSP vs LPL Comparison

Compare CRSP & LPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • LPL
  • Stock Information
  • Founded
  • CRSP 2013
  • LPL 1985
  • Country
  • CRSP Switzerland
  • LPL South Korea
  • Employees
  • CRSP N/A
  • LPL N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • LPL Industrial Machinery/Components
  • Sector
  • CRSP Health Care
  • LPL Technology
  • Exchange
  • CRSP Nasdaq
  • LPL Nasdaq
  • Market Cap
  • CRSP 3.3B
  • LPL 2.9B
  • IPO Year
  • CRSP 2016
  • LPL 2004
  • Fundamental
  • Price
  • CRSP $36.29
  • LPL $3.18
  • Analyst Decision
  • CRSP Buy
  • LPL Sell
  • Analyst Count
  • CRSP 16
  • LPL 2
  • Target Price
  • CRSP $73.07
  • LPL N/A
  • AVG Volume (30 Days)
  • CRSP 2.1M
  • LPL 195.4K
  • Earning Date
  • CRSP 05-06-2025
  • LPL 05-15-2025
  • Dividend Yield
  • CRSP N/A
  • LPL N/A
  • EPS Growth
  • CRSP N/A
  • LPL N/A
  • EPS
  • CRSP N/A
  • LPL N/A
  • Revenue
  • CRSP $37,675,000.00
  • LPL $18,624,457,609.00
  • Revenue This Year
  • CRSP $26.79
  • LPL N/A
  • Revenue Next Year
  • CRSP $297.32
  • LPL N/A
  • P/E Ratio
  • CRSP N/A
  • LPL N/A
  • Revenue Growth
  • CRSP N/A
  • LPL 23.70
  • 52 Week Low
  • CRSP $30.04
  • LPL $2.43
  • 52 Week High
  • CRSP $67.88
  • LPL $4.86
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 46.12
  • LPL 60.34
  • Support Level
  • CRSP $35.38
  • LPL $2.97
  • Resistance Level
  • CRSP $38.13
  • LPL $3.10
  • Average True Range (ATR)
  • CRSP 1.73
  • LPL 0.07
  • MACD
  • CRSP -0.03
  • LPL 0.00
  • Stochastic Oscillator
  • CRSP 26.30
  • LPL 73.21

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES

LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.

Share on Social Networks: